EVISTA

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, UK.

Active ingredients

The drug EVISTA contains one active pharmaceutical ingredient (API):

1	Raloxifene UNII 4F86W47BR6 - RALOXIFENE HYDROCHLORIDE
	As a selective oestrogen receptor modulator (SERM), raloxifene has selective agonist or antagonist activities on tissues responsive to oestrogen. It acts as an agonist on bone and partially on cholesterol metabolism (decrease in total and LDL-cholesterol), but not in the hypothalamus or in the uterine or breast tissues.
	Read more about Raloxifene

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
EVISTA Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)
EVISTA Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
G03XC01	Raloxifene	G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03X Other sex hormones and modulators of the genital system → G03XC Selective estrogen receptor modulators
Discover more medicines within G03XC01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	8363E
BR	Câmara de Regulação do Mercado de Medicamentos	507601201115215, 507601202111213, 507601204114317
CA	Health Products and Food Branch	02239028
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	2515-MEE-0117
EE	Ravimiamet	1038394, 1064135, 1209710, 1209721
ES	Centro de información online de medicamentos de la AEMPS	98073002
FR	Base de données publique des médicaments	67365141
GB	Medicines & Healthcare Products Regulatory Agency	199994
HK	Department of Health Drug Office	44728
IE	Health Products Regulatory Authority	24432, 24527, 24552, 24564, 24592, 24607
IL	מִשְׂרַד הַבְּרִיאוּת	3618
IT	Agenzia del Farmaco	034153015, 034153027
JP	医薬品医療機器総合機構	3999021F1023
LT	Valstybinė vaistų kontrolės tarnyba	1003008, 1028049, 1028050, 1028051
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	586M97
NL	Z-Index G-Standaard, PRK	50881
NZ	Medicines and Medical Devices Safety Authority	7175
PL	Rejestru Produktów Leczniczych	100089480
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W53455001, W53455002, W53455003, W53455004
SG	Health Sciences Authority	10872P
US	FDA, National Drug Code	0002-4184
ZA	Health Products Regulatory Authority	32/34/0422